Our Research Trials

Our clinical trials and studies

Research is fundamental to advancing medicine and improving care for people affected by memory problems. At MARC, every study we deliver brings us closer to better treatments and a future cure for dementia.

Study Participant

I decided to participate in a dementia research study after being diagnosed with Alzheimer’s disease. The comprehensive assessments and screenings not only helped me to understand my condition better but also made me feel proactive in managing my health. The researchers at MARC were compassionate and knowledgeable. Being part of the research also gave me a sense of purpose, knowing that my involvement could contribute to finding better treatments and understanding for future generations”.

We lead pioneering clinical and observational studies aimed at understanding, diagnosing, and treating dementia-related conditions. With over 35 years of research expertise, our team works with national and global partners to explore promising therapies for Alzheimer’s disease, Lewy body dementia, and Mild Cognitive Impairment.

Open Trials

Closed Trials

Our Open Trials

Open to new volunteers

Interested in taking part? Contact us to enquire about our trials and find out if you may be eligible.

MK22114-004

MK2214-004 is a placebo-controlled trial testing MK-2214 to treat Alzheimer’s disease in people Mild Cognitive Impairment or mild dementia due to early Alzheimer’s disease.

READ-OUT

READ-OUT is an observational study evaluating: 1) how good blood tests for dementia are in terms of supporting a dementia diagnosis; 2) how well these tests perform in a real-world population (i.e., people from minority groups, who have significant medical conditions, are of advanced age); 3) whether the blood tests for dementia are good value for money for the NHS.

TopHat

TopHat is a trial that aims to determine whether Ondansetron, a drug already used in the NHS as an anti-sickness treatment, will be both effective and well tolerated as a treatment for visual hallucinations in people with Parkinson’s or Lewy Body Dementia.

BRIC

BRIC is an observational study investigating how inflammation might play a role in cognitive problems for people with Lewy body dementia.

COBALT

COBALT is a placebo-controlled trial investigating whether Memantine improves health and functioning for people with dementia with Lewy bodies. Memantine is already licensed to help treat symptoms in Alzheimer's disease.

Closed Trials

POLARIS-AD

POLARIS-AD is a placebo-controlled trial investigating whether the drug, AR1001, may help the blood vessels in the brain work better for people with Alzheimer's disease.

EVOKE and EVOKE Plus

EVOKE and EVOKE Plus are placebo-controlled trials investigating whether the drug, Semaglutide, may help with cognition and daily functioning.

CLARITY-AD

CLARITY-AD is a placebo-controlled trial in the Open Label Extension Phase, investigating whether the drug, Lecanemab, helps slow the progression of Alzheimer’s disease.

TrailRunner

TrailRunner is a placebo-controlled trial evaluating whether the drug Remternetug is safe and effective at slowing the onset of Alzheimer’s disease in people who are at risk.

TRAILBLAZER5

TRAILBLAZER5 is a placebo-controlled trial investigating whether the drug, Donanemab, may help slow the progression of Alzheimer’s disease.

COGNIKET-MCI

COGNIKET-MCI is a placebo-controlled trial investigating whether ketones and B vitamins help cognitive function for people with Mild Cognitive Impairment.

On-going Trials

No longer recruiting

Interested in finding out more about the progression of these trials? Contact us to enquire.